ual antiplatelet therapy with aspirin and an adenosine diphosphate (ADP) receptor inhibitor is a mainstay of pharmacological therapy in acute coronary syndromes (ACS). [1] [2] [3] In aspirin-treated patients with non-ST-segmentelevation ACS, the co-administration of the P2Y 12 ADP receptor antagonist clopidogrel reduced the composite of cardiovascular death, myocardial infarction, and stroke by 20% compared with placebo. 4 The newer ADP receptor inhibitors prasugrel and ticagrelor yielded an even greater reduction of ischemic outcomes in ACS patients than clopidogrel at the expense of a significantly increased bleeding risk.
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ual antiplatelet therapy with aspirin and an adenosine diphosphate (ADP) receptor inhibitor is a mainstay of pharmacological therapy in acute coronary syndromes (ACS). [1] [2] [3] In aspirin-treated patients with non-ST-segmentelevation ACS, the co-administration of the P2Y 12 ADP receptor antagonist clopidogrel reduced the composite of cardiovascular death, myocardial infarction, and stroke by 20% compared with placebo. 4 The newer ADP receptor inhibitors prasugrel and ticagrelor yielded an even greater reduction of ischemic outcomes in ACS patients than clopidogrel at the expense of a significantly increased bleeding risk. [5] [6] [7] The latter is particularly problematic in patients who cannot be treated by percutaneous coronary intervention (PCI) but must immediately undergo coronary artery bypass graft surgery. Despite these recent advances, ischemic events like acute stent thrombosis still impair the prognosis of many ACS patients. Consequently, to minimize the risk of thrombotic and bleeding complications in the initial phase of ACS, there is still a need for rapidly acting and reversible but highly potent antiplatelet agents.
See accompanying editorial on page 427
Currently approved ADP receptor inhibitors target only the P2Y 12 receptor, but not the other platelet ADP receptor, P2Y 1 . 8 P2Y 1 activation initiates ADP-induced platelet aggregation and is responsible for platelet shape change, 9 whereas P2Y 12 activation results in amplification and stabilization of the aggregation response. There is a complex interplay between P2Y 1 and P2Y 12 , 10 and co-activation of both is necessary for full platelet aggregation.
11 P2Y 1 -selective antagonists have been identified, 12, 13 but the lack of clinical candidates contrasts with the essential role of P2Y 1 in platelet aggregation. March 2016
Adenosine tetraphosphate (Ap4A) is a naturally occurring compound in mammalian tissues. 15 In human platelets, Ap4A is stored in dense granules and, therefore, released along with ADP and ATP upon platelet activation. 16, 17 Ap4A and its analogs have a very short plasma half-life and are known to inhibit ADP-induced platelet activation. 18, 19 Specifically, they inhibit the ADP-induced platelet release reaction, calcium mobilization, thromboxane production, and platelet factor 3 activities. 18 However, Ap 4 A also acts as a P2X1 receptor agonist, an undesirable effect for potential antithrombotic drugs. 20 We recently reported that Ap4A and its derivatives synergistically inhibit both human platelet P2Y 1 and P2Y 12 receptors and efficiently antagonize ADP-induced human platelet aggregation. 20, 21 In a subsequent study, a series of new Ap4A analogs with modifications in the tetraphosphate chain and/or 2-or N 6 -positions in the base were synthesized and evaluated as platelet aggregation inhibitors and with respect to their effects on platelet P2Y 1 , P2Y 12 , and P2X1 receptors. 22 The established structure-activity relations were used to design Ap 4 A analogs which potently inhibit human platelet aggregation by simultaneously targeting platelet P2Y 1 and P2Y 12 ADP receptors but, unlike Ap 4 A, do not activate the platelet P2X1 receptor. The new Ap 4 A analogs can be administered intravenously and act reversibly, and they show significantly higher plasma stability than Ap 4 A. 22 Because of their unique and reversible mechanism of action, their route of administration, the fast onset of their antiplatelet effect, and their short plasma halflife, these new compounds may be beneficial in clinical situations where a high atherothrombotic risk and an increased bleeding risk coincide. Accordingly, they are envisioned as a future treatment option in the initial phase of ACS. However, data on the antithrombotic effect of the new Ap 4 A analogs in vivo, as well as on agonist-induced platelet aggregation, without and with concomitant aspirin treatment are missing, to date. Based on its pharmacokinetic and pharmacodynamic profile, we therefore selected compound GLS-409 from the newly discovered Ap 4 A derivatives for further studies on antiplatelet efficacy. Specifically, we investigated (1) the effect of GLS-409, administered in vivo to anesthetized rats, on ex vivo agonist-stimulated platelet aggregation, (2) the antithrombotic activity of GLS-409 and the associated effect on the bleeding time in a canine model of recurrent platelet-mediated coronary artery thrombosis mimicking unstable angina, [23] [24] [25] [26] and (3) the inhibition of agonist-stimulated platelet aggregation by GLS-409 versus selective P2Y 1 and P2Y 12 inhibition in vitro in samples from healthy human subjects before and 2 hours after aspirin intake.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Protocol 1. Rat Model of In Vivo TreatmentEx Vivo Platelet Aggregation
There were no significant differences in heart rate or arterial pressures in GLS-409-treated groups versus saline controls (see Figure I in the online-only Data Supplement).
In vivo administration of GLS-409 inhibited ex vivo ADP-stimulated platelet aggregation in a dose-dependent manner, with approximately complete inhibition, assessed at 10 minutes after addition of the agonist, achieved with 0.054 mg/kg bolus+0.0018 mg/kg per min infusion and doses 10×, 100×, and 300× higher than this threshold dose (Table 1 ). In contrast, the effect of GLS-409 on collagen-induced platelet aggregation was modest and manifest only at 1/4, 1, and 10× the threshold dose: that is, the agent had no effect on collagen-stimulated aggregation at either low or high doses ( 
Protocol 2. Canine Model of Recurrent Coronary Thrombosis
As in the rat model, there were no differences in heart rate or arterial pressures in the GLS-409-treated group when compared with saline controls at any time during the 3-hour observation period (all P values for group >0.22; Figure 1 ). As expected, all dogs developed cyclic variations in coronary blood flow (ie, spontaneous episodes of recurrent thrombosis) after coronary injury+stenosis ( Figure 2 ). During the 1 hour pretreatment period, coronary patency was comparable in dogs later assigned to receive GLS-409 versus saline: flowtime area was 30±5% versus 28±4%, and zero flow duration was 22±6% versus 21±5%, respectively ( Figure 3 ). In addition, template bleeding times assessed before the onset of treatment were similar in both groups (mean of 90-93 s; Figure 4 ).
The saline-control group displayed no change in coronary patency or template bleeding time during the 2 hour treatment period when compared with the pretreatment phase ( Figures 3  and 4 ). In contrast, administration of GLS-409 evoked a significant increase in flow-time area (to 60±10%; P<0.05 versus pretreatment and P<0.05 versus controls) together with a decrease in zero flow duration (to <1%; P value for group =0.14; Figures 2 and 3 ). The effect of GLS-409 on template bleeding time was variable, averaging 160±48 s at 2 hours post-treatment (P value for group =0.26; Figure 4 ).
Protocol 3. Effect of GLS-409 Versus Selective P2Y 1 and P2Y 12 Inhibition on AgonistStimulated Human Platelet Aggregation In Vitro Before and 2 Hours After Aspirin Intake
In the third component of the study, we compared the effects of GLS-409 to those of the selective P2Y 1 inhibitor MRS 2179 and to those of the selective P2Y 12 inhibitor cangrelor on ADP-, collagen-, and thrombin receptor-activating peptide (TRAP)-stimulated platelet aggregation in platelet-rich plasma (PRP) from 6 healthy donors before and 2 hours after the intake of 325 mg of uncoated aspirin. Moreover, we compared the effects of GLS-409 to those of the combination of cangrelor with 5 μmol/L of MRS 2179 on ADP-, collagen-, and TRAP-stimulated platelet aggregation in PRP from 3 healthy donors pre-and post-aspirin. The inhibition of both platelet ADP receptors by GLS-409 had similar effects to those of cangrelor and the combination of cangrelor with 5 μmol/L of MRS 2179 on ADP-, collagen-and TRAP-stimulated maximal and final platelet aggregation in PRP without and with aspirin treatment (Figures 5 and 6 ). GLS-409, cangrelor, and the combination of cangrelor with 5 μmol/L of MRS 2179 inhibited maximal and final platelet aggregation in response to all agonists pre-and post-aspirin more strongly than the selective P2Y 1 antagonist MRS2179 (Figures 5 and 6 ). The IC 50 s for ADP-, collagen-, and TRAP-stimulated platelet aggregation were lower with GLS-409 compared with cangrelor and MRS 2179, but similar to the combination of cangrelor with 5 μmol/L of MRS 2179 before and 2 hours after the intake of aspirin (Tables 2 and 3 ). Inhibition of ADP-and collagenstimulated platelet aggregation by GLS-409 in PRP was not significantly altered by aspirin treatment, whereas the IC 50 for TRAP-stimulated aggregation with GLS-409 decreased after the administration of aspirin to healthy donors (Tables 2 and  3 ). Selective inhibition of P2Y 1 by MRS 2179 at the tested concentrations showed no inhibition of collagen-and TRAPstimulated aggregation in PRP from aspirin-free healthy donors. In contrast, 2 hours after the administration of aspirin, ADP-and collagen-stimulated platelet aggregation was inhibited to a similar extent in PRP from healthy donors concomitantly treated with MRS 2179 (Figures 5 and 6 ).
Finally, we compared the effects of GLS-409 to those of the selective P2Y 1 inhibitor MRS 2179 and to those of the selective P2Y 12 inhibitor cangrelor on ADP-and TRAPstimulated platelet aggregation in whole blood from 6 healthy donors pre-and post-aspirin intake. GLS-409 showed effects similar to those of cangrelor on ADP-and TRAP-stimulated platelet aggregation, and both had more pronounced effects than MRS 2179 on agonist-stimulated platelet aggregation ( Figure 7) . Inhibition of ADP-stimulated aggregation by GLS-409 in whole blood was not significantly altered by aspirin treatment, whereas the IC 50 for TRAP-stimulated aggregation with GLS-409 decreased after the administration of aspirin to healthy donors (Table 4) . Similar to the results in PRP, selective inhibition of P2Y 1 by MRS 2179 at the tested concentrations showed no inhibition of TRAP-stimulated platelet aggregation pre-and post-aspirin treatment ( Figure 7 ).
Discussion
Our study is the first to investigate the effects of synergistic P2Y 1 and P2Y 12 receptor inhibition by a single compound (GLS-409) on agonist-stimulated platelet aggregation in rats and on recurrent coronary artery thrombosis in a canine model of unstable angina. In addition, we studied the antiplatelet effect of GLS-409 versus selective P2Y 1 and P2Y 12 receptor antagonists on agonist-stimulated platelet aggregation in PRP and whole blood from healthy human donors in vitro before and 2 hours after aspirin intake. In vivo treatment with GLS-409 significantly inhibited ADP-and collagen-stimulated platelet aggregation in rats. Furthermore, GLS-409, administered intravenously after coronary stenosis and injury, evoked an immediate and significant attenuation of platelet-mediated thrombosis in vivo in our canine model of unstable angina. The improvement in coronary patency was accompanied by a nonsignificant 30% increase in the median bleeding time, an observation that must be interpreted with caution given the small n value of 4 per group and variability in the data. GLS-409 showed a rapid biphasic plasma clearance with a first phase half-life of 9.7 minutes and a second phase half-life of 58 minutes. Of note, GLS-409 exerted its effects in vivo without affecting rat or canine hemodynamics, respectively.
Finally, in vitro treatment with GLS-409 showed effects similar to that of cangrelor and the combination of cangrelor with MRS 2179 on agonist-stimulated platelet aggregation in human PRP and whole blood. The inhibition of ADP-and collagen-stimulated platelet aggregation by GLS-409 in PRP and the inhibition of ADP-stimulated platelet aggregation in whole blood were not altered by aspirin treatment, whereas the IC 50 s for TRAP-stimulated platelet aggregation in PRP and whole blood with GLS-409 decreased after the administration of aspirin to healthy donors. P2Y 1 is widely expressed in different tissues, where it is involved in the control of various functions. 27 Therefore, it is of utmost importance for antiplatelet drug candidates inhibiting P2Y 1 to avoid adverse effects associated with nonplatelet P2Y 1 targeting. Because GLS-409 inhibited agoniststimulated human platelet aggregation at levels at which P2Y 1 was not significantly inhibited in our study, such side effects seem unlikely with this agent. Specifically, the IC 50 for ADP-stimulated platelet aggregation with the P2Y 1 inhibitor MRS 2179 was significantly higher compared with GLS-409. Moreover, selective blockage of P2Y 1 by MRS 2179 did not affect platelet activation by TRAP and, in line with a previous publication by Mangin et al, 28 inhibited collagen-stimulated platelet aggregation only in samples from aspirin-treated healthy donors. These findings suggest that P2Y 1 inhibition alone may not effectively prevent agonist-stimulated platelet aggregation at acceptable plasma concentrations. Zhang et al recently investigated the crystal structures of human P2Y 1 in complex with a nucleotide antagonist MRS 2500 and with a non-nucleotide antagonist BPTU (1-(2-(2-(tertbutyl)phenoxy)pyridin-3-yl)-3-(4-(trifluoromethoxy)phenyl) urea), thereby revealing 2 disparate ligand-binding sites of the receptor. 29 Although MRS 2500 and BPTU bind to distinct sites in P2Y 1 , both ligands stabilize the receptor in similar inactive conformations. Nevertheless, future studies are needed to determine whether nucleotide and non-nucleotide antagonists exert similar antiplatelet effects at P2Y 1 . Because GLS-409 acts as a nucleotide antagonist at P2Y 1 , we chose another nucleotide antagonist (MRS 2179) as a comparator for our experiments in aspirin-free and aspirin-treated samples from healthy volunteers.
Activation of P2Y 12 by ADP inhibits adenylyl cyclase through activation of the G αi2 G-protein subtype. 30 Thus, P2Y 12 activation counteracts the antiplatelet effects of prostacyclin, which inhibits platelet function by increasing the levels of cyclic adenosine monophosphate through activation of adenylyl cyclase. Consequently, P2Y 12 receptor inhibitors exert their antithrombotic effects in part by fostering the antiplatelet potency of prostacyclin. 31 By inhibiting prostacyclin synthesis of endothelial cells, concomitant aspirin therapy may attenuate the antiplatelet effects of P2Y 12 inhibition. Indeed, it has been speculated that the combination of ticagrelor with high-dose aspirin at many study sites in North America in the PLATO (Platelet Inhibition and Patient Outcomes) trial may have been responsible for the less pronounced effects of ticagrelor on the reduction of adverse ischemic events compared with study sites in the rest of the world. 32 Because ADP receptor antagonists are typically used in conjunction with aspirin in ACS, 3 it is important to show that concomitant aspirin therapy does not reduce the antiplatelet potency of new drugs targeting P2Y 12 . We, therefore, assessed the inhibition of agonist-stimulated human platelet aggregation by GLS-409 in samples drawn before and 2 hours after the intake of 325 mg of uncoated aspirin. In our study, inhibition of ADP-stimulated platelet aggregation by GLS-409 was similar in PRP and whole blood, and inhibition of collagen-stimulated platelet aggregation by GLS-409 was similar in PRP before and 2 hours after aspirin intake. Furthermore, the IC 50 s for TRAP-stimulated platelet aggregation in PRP and whole blood with GLS-409 decreased after pretreatment with aspirin. These findings suggest that the strong antiplatelet effects of GLS-409 are retained in aspirintreated subjects. Synergistic inhibition of P2Y 1 and P2Y 12 by GLS-409 is envisioned as an antiplatelet strategy for the initial phase of ACS. When patients suffer an ACS, they are in a prothrombotic state initiated by the rupture of an atherosclerotic plaque with subsequent coronary artery stenosis and occlusion. In this situation, rapid platelet inhibition is critical to prevent further prothrombotic actions. Moreover, most patients with ACS currently undergo PCI with implantation of a drug-eluting stent. This procedure is associated with a further increased risk of ischemic events, for example, acute stent thrombosis, and, therefore, requires a fast, strong, and consistent antiplatelet therapy. In contrast to the oral antiplatelet agents prasugrel and ticagrelor, GLS-409 is administered intravenously, thereby avoiding the need for intestinal absorption. Consequently, GLS-409 is able to immediately exert its antiplatelet effect, which may be associated with a further reduction of thrombotic events in the initial phase of ACS compared with oral ADP receptor antagonists. Alternatively, GLS-409 could serve as additional intravenous treatment for high-risk patients who are already on prasugrel or ticagrelor.
On the other hand, some patients develop serious bleeding complications while being treated with antithrombotic therapy. Other patients are not eligible for PCI and stent implantation because of their coronary artery anatomy and require emergency coronary artery bypass graft surgery. In these cases, the fast restoration of platelet function would be of great importance. Becasue GLS-409 has a much shorter plasma half-life than prasugrel and ticagrelor, 22, 33 its use may result in a significant reduction of serious bleeding events compared with the clinically approved, oral P2Y 12 inhibitors in the above-mentioned patient populations. In contrast to prasugrel, ticagrelor, and cangrelor, GLS-409 targets not only P2Y 12 but also the second platelet ADP receptor P2Y 1 and may, therefore, provide a more complete inhibition of ADP-induced human platelet aggregation. Our findings indicate that because of the synergistic nature of this inhibition of platelet aggregation, therapeutic inhibition may be achieved at lower concentrations of drug and lower blockade of P2Y 1 and P2Y 12 than with agents that only block P2Y 1 or P2Y 12 . One may speculate that a more comprehensive inhibition of ADP-induced platelet aggregation at lower drug concentrations will be associated with an improved benefit/risk ratio. However, large randomized clinical trials are needed to reveal the potential benefits of the presently described combined inhibition of P2Y 1 and P2Y 12 compared with the currently Food and Drug Administration-approved solely P2Y 12 blockers. Of particular interest would be a clinical study comparing GLS-409 to the intravenous P2Y 12 receptor antagonist cangrelor in the initial phase of ACS because the latter yielded heterogeneous results in large clinical trials. Although cangrelor was not superior to an oral loading dose of 600 mg clopidogrel in reducing the composite of death from any cause, myocardial infarction, or ischemia-driven revascularization at 48 hours in ACS patients undergoing PCI, 34 it significantly reduced the composite of death, myocardial infarction, ischemia-driven revascularization, or stent thrombosis at 48 hours compared with clopidogrel in patients undergoing urgent or elective PCI. 35 In both studies, the use of cangrelor was not associated with a significantly increased risk of severe bleeding compared with clopidogrel. Moreover, the use of periprocedural cangrelor during PCI was not superior to placebo in reducing the composite of death from any cause, myocardial infarction, or ischemia-driven revascularization at 48 hours, but significantly reduced the secondary end points of stent thrombosis and death from any cause, albeit at a significantly increased bleeding risk. 36 It remains to be established whether, because of its unique mechanism of action, GLS-409 can provide additional reduction of the ischemic risk beyond intravenous P2Y 12 blockade at an acceptable bleeding risk. Our data demonstrate the antithrombotic efficacy of GLS-409 in vivo and show that it rapidly and potently inhibits agonist-stimulated human platelet aggregation in vitro with and without concomitant aspirin therapy. Moreover, GLS-409 did not affect hemodynamics in our rat and canine model and was only associated with a moderate nonsignificant increase in median bleeding time in our canine model, while showing a fast plasma clearance. These findings, together with the previous data on its high plasma stability and reversibility of its antiplatelet effects, 22 suggest that GLS-409 could become a meaningful addition to the current pharmacological armamentarium in ACS. Presently, GLS-409 is undergoing late-stage preclinical evaluation with a particular focus on the transition from GLS-409 to clinically approved, oral P2Y 12 inhibitors with a goal of initiating human clinical testing in near future. In conclusion, synergistic inhibition of both P2Y 1 and P2Y 12 ADP receptors by GLS-409 immediately attenuates platelet-mediated thrombosis and effectively blocks agoniststimulated platelet aggregation irrespective of concomitant aspirin therapy. GLS-409 is, therefore, a promising antiplatelet drug candidate, in particular, for the initial phase of ACS.
Sources of Funding
Funding was provided by National Institutes of Health (NIH) SBIR grants R44HL088828 and R44TR000983 to I.B. Yanachkov. K. Przyklenk was supported in part by NIH R01HL072684.
